<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240124060790N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-14</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of insulin injection,amniotic membrane and simple dressing with petroleum gauze in wound healing</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of three methods of subcutaneous injection of insulin and amnion membrane and simple dressing with petroleum jelly in the repair of donor graft site in second and third degree burns in a period of one year in Taleghani Hospital of Ahvaz</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75205</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study will be conducted on 120 patients and the intervention and control will be on one patient. Considering the width of the dermatome at 9 cm and the length of the skin graft at least 15 cm with relative thickness, three sections of 5 x 9 cm in the proximal, medial and distal of the wound will be randomly selected as cases and controls. Insulin, placebo (normal saline serum) will be used subcutaneously and amnion membrane as a cover in the proximal, medial and distal areas of the mentioned wound. 
 Description of how to randomize: Using the table of random numbers, case and control groups are randomly selected between proximal wound, medial wound and distal wound.</study_design>
      <phase>2</phase>
      <hc_freetext>2rd and 3rd degree burns.</hc_freetext>
      <i_freetext>Intervention 1: Description of the intervention in the case group: NPH insulin made by Elixir factory will be injected subcutaneously in a single dose with a concentration of 1 unit per milliliter with a dose of 2 cc in 10 points. After the intervention, the wounds of the dressing patients become clear. . In addition, blood sugar measurement will be done in order to prevent side effects such as hypoglycemia in patients before and after surgery. Intervention 2: Control group:( Description of the intervention of the control group): The placebo in this study is normal saline serum, which will be injected subdermally in 10 points with a volume of 2 cc as a single dose like insulin. After the intervention, the wounds of the dressing patients become clear. On the 7th, 14th, and 21st days after the operation, the wound will be examined and a picture of the position will be taken. Intervention 3: Intervention group: In the other intervention group, the amniotic membrane is used as a wound cover. On the 7th, 14th, and 21st days after the operation, the wound will be examined and a picture of the position will be taken.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Until final conclusions can not be spoken about the data dissemination</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali alizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani burn hospital, Hejrat blvd., Padadshahr 2 phase</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6187954386</zip>
        <telephone>+98 61 3554 7992</telephone>
        <email>alizadeh.ali@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahtab farhadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani burn hospital, Hejrat blvd., Padadshahr 2 phase</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6187954386</zip>
        <telephone>+98 61 3554 7992</telephone>
        <email>alizadeh.ali@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients between 18 to 65,
Patients with second and third degree burn</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant women
Patients with underlying diseases such as Diabetes, chronic kidney disease، chronic liver disease, peripheral vascular disease, cardiovascular disease, collagen vascular disease, chronic skin disease ranging from autoimmune diseases to skin malignancies
Heavy smokers
Immunosuppressive medication users</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T20. 20XA-</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>T20. 20XA:Burn of second degree of head, face, and neck, unspecified site, initial encounter.   T21. 30XA :Burn of third degree of trunk, unspecified site, initial encounter. T86.822 :for skin graft (allograft)(autograft)</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Description of the intervention in the case group: NPH insulin made by Elixir factory will be injected subcutaneously in a single dose with a concentration of 1 unit per milliliter with a dose of 2 cc in 10 points. After the intervention, the wounds of the dressing patients become clear. . In addition, blood sugar measurement will be done in order to prevent side effects such as hypoglycemia in patients before and after surgery</i_keyword>
      <i_keyword>Control group:( Description of the intervention of the control group): The placebo in this study is normal saline serum, which will be injected subdermally in 10 points with a volume of 2 cc as a single dose like insulin. After the intervention, the wounds of the dressing patients become clear. On the 7th, 14th, and 21st days after the operation, the wound will be examined and a picture of the position will be taken</i_keyword>
      <i_keyword>Intervention group: In the other intervention group, the amniotic membrane is used as a wound cover. On the 7th, 14th, and 21st days after the operation, the wound will be examined and a picture of the position will be taken.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The area of ​​the epithelialized area to follow the condition of the wound. Timepoint: مقاطع زمانی اندازه‌گیری :روز 7، 14 و 21 پس از انجام مطالعه. Method of measurement: Examining the area of ​​the epithelialized area using ImageJ software.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-06</approval_date>
        <contact_name>Ethics committee Ahvaz Jondishapur University of Medical Sciences</contact_name>
        <contact_address>Taleghani Burn hospital, Hejrat blvd., Padadshar 2 phase Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
